David Merschin1, Richard Häne2, Mersedeh Tohidnezhad3, Thomas Pufe3, Wolf Drescher2. 1. Clinic for Trauma Surgery and Orthopaedics, BG Klinikum Unfallkrankenhaus Berlin, Warener Straße 7, Berlin, Germany. david.merschin@gmx.de. 2. Department of Orthopaedic Surgery of the Lower Limb and Arthroplasty, Hospital Rummelsberg, Rummelsberg 71,, Schwarzenbruck, Germany. 3. Institut für Anatomie und Zellbiologie, Uniklinik RWTH Aachen, Pauwelsstraße 30, 52074, Aachen, Germany.
Abstract
PURPOSE: Short-stem hip arthroplasty has the potential advantage of femoral bone stock preservation, especially in view of the expected revisions in the often relatively young patients. Despite short-stem hip prosthesis are increasingly used for total hip arthroplasty, there are no sufficient mid- and long-term results especially for patients with avascular femoral head osteonecrosis. The present study investigates mid-term functional results as well as the revision rate following implantation of a short-stem prosthesis. METHODS: In the period 06/2005 until 12/2013, a total of 351 short-stem hip prostheses were implanted. The study included 331 complete data sets. A retrospective analysis was performed using the Oxford Hip Score. All revisions were registered. RESULTS: In a total of 331 prostheses, the Oxford Hip Score was "excellent" in 66.2%, "good" in 12.7%, "fair" in 13.0%, and "poor" in 8.2% with a mean follow-up of 57.4 months (SD ± 29.8; range 24-115). In 26 cases, aseptic osteonecrosis of the hip was the indication (7.9%). The Oxford Hip Score was "excellent" in 66.7%, "good" in 0.0%, "fair" in 20.8%, and "poor" in 12.5%. The cumulated five year survival rate was 96.7%. CONCLUSION: In mid-term observation, the Metha® short-stem prosthesis shows no disadvantage in functional outcome and in survival time compared to a standard hip stem. Providing a correct indication, the Metha® short stem is a valuable option in total hip arthroplasty for younger patients with avascular osteonecrosis of the femoral head. Evaluation has shown no significant differences between aseptic osteonecrosis and other indications.
PURPOSE: Short-stem hip arthroplasty has the potential advantage of femoral bone stock preservation, especially in view of the expected revisions in the often relatively young patients. Despite short-stem hip prosthesis are increasingly used for total hip arthroplasty, there are no sufficient mid- and long-term results especially for patients with avascular femoral head osteonecrosis. The present study investigates mid-term functional results as well as the revision rate following implantation of a short-stem prosthesis. METHODS: In the period 06/2005 until 12/2013, a total of 351 short-stem hip prostheses were implanted. The study included 331 complete data sets. A retrospective analysis was performed using the Oxford Hip Score. All revisions were registered. RESULTS: In a total of 331 prostheses, the Oxford Hip Score was "excellent" in 66.2%, "good" in 12.7%, "fair" in 13.0%, and "poor" in 8.2% with a mean follow-up of 57.4 months (SD ± 29.8; range 24-115). In 26 cases, aseptic osteonecrosis of the hip was the indication (7.9%). The Oxford Hip Score was "excellent" in 66.7%, "good" in 0.0%, "fair" in 20.8%, and "poor" in 12.5%. The cumulated five year survival rate was 96.7%. CONCLUSION: In mid-term observation, the Metha® short-stem prosthesis shows no disadvantage in functional outcome and in survival time compared to a standard hip stem. Providing a correct indication, the Metha® short stem is a valuable option in total hip arthroplasty for younger patients with avascular osteonecrosis of the femoral head. Evaluation has shown no significant differences between aseptic osteonecrosis and other indications.
Entities:
Keywords:
Avascular necrosis; Hip; Short-stem hip arthroplasty
Authors: Stefan Budde; Thilo Floerkemeier; Fritz Thorey; Marco Ezechieli; Leif Claassen; Max Ettinger; Jan Bredow; Henning Windhagen; Gabriela von Lewinski Journal: Technol Health Care Date: 2016-03-18 Impact factor: 1.285
Authors: Laura Augustin; Sarah Boller; Cathrein Bobach; Alexander Jahnke; Gafar Adam Ahmed; Markus Rickert; Bernd Alexander Ishaque Journal: Int Orthop Date: 2018-09-03 Impact factor: 3.075
Authors: Philippe Hernigou; Benjamin Thiebaut; Victor Housset; Claire Bastard; Yasuhiro Homma; Younes Chaib; Charles Henri Flouzat Lachaniette Journal: Int Orthop Date: 2018-04-26 Impact factor: 3.075
Authors: Philippe Hernigou; Arnaud Dubory; Yasuhiro Homma; Isaac Guissou; Charles Henri Flouzat Lachaniette; Nathalie Chevallier; Hélène Rouard Journal: Int Orthop Date: 2018-05-09 Impact factor: 3.075
Authors: Philippe Hernigou; Guillaume Rigoulot; Jean Charles Auregan; Victor Housset; Claire Bastard; Arnaud Dubory; Charles Henri Flouzat Lachaniette Journal: SICOT J Date: 2018-11-05
Authors: Josef Hochreiter; Harald Kindermann; Mattiassich Georg; Reinhold Ortmaier; Marian Mitterer Journal: Int Orthop Date: 2019-07-27 Impact factor: 3.075
Authors: Marek Drobniewski; Marek Synder; Marek Aleksander Synder; Magdalena Krasińska; Lukasz Olewnik; Andrzej Borowski Journal: Sci Rep Date: 2021-11-05 Impact factor: 4.379